Biotie has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a $1.0 million milestone payment to Biotie. Timo Veromaa, president and chief executive officer of Biotie, said, “We are pleased with the progress we have made in collaboration with Wyeth on the PDE10 inhibitor program and look forward to beginning our work together in the clinic. We believe this partnership provides further validation for...